AR064008A1 - Metodo para el diagnostico y tratamiento del glioma - Google Patents
Metodo para el diagnostico y tratamiento del gliomaInfo
- Publication number
- AR064008A1 AR064008A1 ARP070105279A ARP070105279A AR064008A1 AR 064008 A1 AR064008 A1 AR 064008A1 AR P070105279 A ARP070105279 A AR P070105279A AR P070105279 A ARP070105279 A AR P070105279A AR 064008 A1 AR064008 A1 AR 064008A1
- Authority
- AR
- Argentina
- Prior art keywords
- pik3r3
- glioma
- polypeptide
- antagonist
- mammal
- Prior art date
Links
- 208000032612 Glial tumor Diseases 0.000 title abstract 8
- 206010018338 Glioma Diseases 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 101001098116 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit gamma Proteins 0.000 abstract 8
- 102100037553 Phosphatidylinositol 3-kinase regulatory subunit gamma Human genes 0.000 abstract 8
- 241000124008 Mammalia Species 0.000 abstract 4
- 239000005557 antagonist Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 239000000523 sample Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 abstract 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 abstract 1
- 239000013068 control sample Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente aborda métodos y composiciones para el diagnostico, pronostico y tratamiento del glioma en mamíferos. Reivindicacion 1: Una composicion que comprende un vehículo, excipiente o estabilizante farmacéuticamente aceptable y cantidades terapéuticamente eficaces de (i) un antagonista del PIK3R3 en combinacion con (ii) un antagonista del IGF2 y, opcionalmente, (iii) un antagonista de la Akt Reivindicacion 3: Un método para diagnosticar la presencia de un glioma en un mamífero, en la que el uso consiste en comparar el nivel de expresion de un polipéptido de PIK3R3 o ácido nucleico que codifique un polipéptido de PIK3R3 en (a) una muestra de prueba o tejido de glioma obtenida de dicho mamífero y que presuntamente es canceroso y (b) una muestra de control de células no cancerosas normales conocidas del mismo origen tisular, considerando que una mayor expresion del polipéptido de PIK3R3 o ácido nucleico que codifique el polipéptido de PIK3R3 en la muestra de prueba, en comparacion con la observada en la prueba de control, indicaría la presencia de un glioma en el mamífero del cual se obtuvo la muestra de prueba. Reivindicacion 16: Uso de una composicion de acuerdo con la reivindicacion 1, para la manufactura de un medicamento util para la inhibicion del crecimiento de un glioma que expresa un polipéptido de PIK3R3, donde el crecimiento de dicho glioma depende, al menos en parte, del efecto o efectos potenciadores del crecimiento de un polipéptido de PIK3R3, donde ese método supone poner en contacto una célula del glioma con una cantidad eficaz de un antagonista del PIK3R3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86776106P | 2006-11-29 | 2006-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064008A1 true AR064008A1 (es) | 2009-03-04 |
Family
ID=39468664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105279A AR064008A1 (es) | 2006-11-29 | 2007-11-28 | Metodo para el diagnostico y tratamiento del glioma |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080221014A1 (es) |
| EP (1) | EP2091565A2 (es) |
| JP (1) | JP2010511060A (es) |
| AR (1) | AR064008A1 (es) |
| AU (1) | AU2007325259A1 (es) |
| CA (1) | CA2669184A1 (es) |
| CL (1) | CL2007003422A1 (es) |
| IL (1) | IL198425A0 (es) |
| MX (1) | MX2009005400A (es) |
| TW (1) | TW200831536A (es) |
| WO (1) | WO2008067351A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130138779A (ko) * | 2010-09-23 | 2013-12-19 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | Ｇｂｍ 환자의 생존율 예측에 유용한 테모졸로미드에 의한 ｔｏｐ2ａ의 저해 |
| CN102321158B (zh) * | 2011-08-23 | 2013-03-27 | 常州德健生物科技有限公司 | 阻止细胞dna合成抑制细胞增殖的多肽及用途 |
| CA2850646A1 (en) | 2011-10-07 | 2013-04-11 | Universite Montpellier 2 Sciences Et Techniques | Prognosis for glioma |
| TWI692777B (zh) * | 2018-11-16 | 2020-05-01 | 長庚醫療財團法人高雄長庚紀念醫院 | 智能化急性腎損傷藥物警示系統 |
| CN111778334A (zh) * | 2020-07-13 | 2020-10-16 | 中山大学孙逸仙纪念医院 | 一种CircRNA作为肝癌肿瘤标志物的评价方法 |
| CN119113120B (zh) * | 2024-09-29 | 2025-07-25 | 首都医科大学附属北京友谊医院 | p55γ作为主动脉夹层治疗靶点的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165170A (en) * | 1998-01-29 | 2000-12-26 | International Business Machines Corporation | Laser dermablator and dermablation |
| MXPA04006980A (es) * | 2002-01-18 | 2004-11-10 | Pf Medicament | Anticuerpos novedosos anti-receptor del factor de crecimiento i tipo insulina, y usos de los mismos. |
| NZ543751A (en) * | 2003-05-23 | 2008-05-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumors of glial origin |
| EP1636212B1 (en) * | 2003-06-05 | 2007-06-27 | Warner-Lambert Company LLC | Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents |
| WO2005054202A1 (en) * | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| AU2006214190A1 (en) * | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| US20080014598A1 (en) * | 2006-07-13 | 2008-01-17 | Cell Signaling Technology, Inc. | Phospho-specific antibodies to pi3k regulatory subunit and uses thereof |
-
2007
- 2007-11-28 WO PCT/US2007/085709 patent/WO2008067351A2/en not_active Ceased
- 2007-11-28 AU AU2007325259A patent/AU2007325259A1/en not_active Abandoned
- 2007-11-28 AR ARP070105279A patent/AR064008A1/es not_active Application Discontinuation
- 2007-11-28 CA CA002669184A patent/CA2669184A1/en not_active Abandoned
- 2007-11-28 JP JP2009539450A patent/JP2010511060A/ja active Pending
- 2007-11-28 MX MX2009005400A patent/MX2009005400A/es not_active Application Discontinuation
- 2007-11-28 CL CL200703422A patent/CL2007003422A1/es unknown
- 2007-11-28 US US11/946,449 patent/US20080221014A1/en not_active Abandoned
- 2007-11-28 TW TW096145233A patent/TW200831536A/zh unknown
- 2007-11-28 EP EP07868886A patent/EP2091565A2/en not_active Withdrawn
-
2009
- 2009-04-27 IL IL198425A patent/IL198425A0/en unknown
- 2009-07-06 US US12/498,181 patent/US20090269351A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007003422A1 (es) | 2008-06-20 |
| WO2008067351A2 (en) | 2008-06-05 |
| WO2008067351A3 (en) | 2008-11-06 |
| AU2007325259A1 (en) | 2008-06-05 |
| MX2009005400A (es) | 2009-06-05 |
| US20090269351A1 (en) | 2009-10-29 |
| EP2091565A2 (en) | 2009-08-26 |
| TW200831536A (en) | 2008-08-01 |
| IL198425A0 (en) | 2010-02-17 |
| CA2669184A1 (en) | 2008-06-05 |
| AU2007325259A2 (en) | 2009-07-02 |
| US20080221014A1 (en) | 2008-09-11 |
| JP2010511060A (ja) | 2010-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064008A1 (es) | Metodo para el diagnostico y tratamiento del glioma | |
| Guzman et al. | The effect of fibrillar matrix architecture on tumor cell invasion of physically challenging environments | |
| Salatto et al. | Selective activation of AMPK β1-containing isoforms improves kidney function in a rat model of diabetic nephropathy | |
| Theiss et al. | Prohibitin protects against oxidative stress in intestinal epithelial cells | |
| Lemke et al. | Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK α is the predominant isoform expressed in human heart | |
| Srinivasan et al. | Oxidative stress induced mitochondrial protein kinase A mediates cytochrome c oxidase dysfunction | |
| ES2573471T3 (es) | 1L1RL-1 como un marcador de enfermedades cardiovasculares | |
| Albert et al. | Effect of PGE1, indomethacin, and polyphloretin phosphate on toad bladder response to ADH | |
| Chen et al. | Umbilical cord‐derived mesenchymal stem cells suppress autophagy of T cells in patients with systemic lupus erythematosus via transfer of mitochondria | |
| Wu et al. | Kappa opioid receptor signaling protects cartilage tissue against posttraumatic degeneration | |
| Ahn et al. | Engineered biomimetic fibrillar fibronectin matrices regulate cell adhesion initiation, migration, and proliferation via α5β1 integrin and syndecan‐4 crosstalk | |
| Huang et al. | LC3B, a protein that serves as an autophagic marker, modulates angiotensin II-induced myocardial hypertrophy | |
| Sloniger et al. | Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG (mREN2) 27 rats | |
| Myszka et al. | Sodium hydrosulfide moderately alleviates the hallmark symptoms of Duchenne muscular dystrophy in mdx mice | |
| Di Costanzo et al. | Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation | |
| Zhang et al. | Mitophagy-mediated inflammation and oxidative stress contribute to muscle wasting in cancer cachexia | |
| Wang et al. | Neuropeptide Y mediates cardiac hypertrophy through microRNA-216b/FoxO4 signaling pathway | |
| Lippi et al. | Depolarization evoked co-release of tachykinins from enteric nerves in the guinea-pig proximal colon | |
| Krammer et al. | Cardioprotective effects of semaglutide on isolated human ventricular myocardium | |
| CN110646615A (zh) | 肝纤维化的生物学标志物、治疗靶点及其用途 | |
| Zhang et al. | Matrix metalloproteinase-9 expression is enhanced in renal parietal epithelial cells of zucker diabetic Fatty rats and is induced by albumin in in vitro primary parietal cell culture | |
| JP2008273955A (ja) | 炎症性腸疾患改善剤 | |
| Ko et al. | Up‐regulation of the tight‐junction protein ZO‐1 by substance P and IGF‐1 in A431 cells | |
| Tiede et al. | Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts | |
| Sampaio et al. | The melatonin analog 5-MCA-NAT increases endogenous dopamine levels by binding NRH: quinone reductase enzyme in the developing chick retina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |